益阴明目合剂稳定眼压及视神经保护机理的研究
|
摘要
目的：用益气养阴明目开窍法治疗中晚期青光眼,并探讨其稳定眼压及视神经保护的作用机制。方法：1.实验研究：用益阴明目合剂给高眼压大鼠灌胃,检测其对高眼压大鼠血浆内皮素(endothelin, ET)、一氧化氮(nitrous oxide, NO)、视网膜超氧化物歧化酶(superoxide dismutase, SOD)、丙二醛(maleic dialdehyde, MDA)和谷氨酸(glutamic acid, Glu)的影响。2.临床研究：用益阴明目合剂治疗中晚期青光眼,通过治疗前后视力、视野、眼压的比较,总结和评价其疗效。结果：1.益阴明目合剂能有效提高急性高眼压大鼠视网膜中SOD活性,降低MDA、Glu含量,降低血浆ET和NO含量。2.益阴明目合剂治疗中晚期青光眼效果显著,总有效率为94.87%。结论：1.益阴明目合剂治疗中晚期青光眼疗效确切；2.益阴明目合剂可能通过清除自由基,增强耐缺氧能力,改善微循环,抑制谷氨酸的释放、降低内皮素含量等作用而起到稳定眼压和视神经保护的作用。
Objective:To treat the glaucoma in middle and advanced stage with the method of YiQiYangYinKaiQiao and to study the mechanism of stabilizing the intraocular pressure and protecting the optic nerve with it.Methods:1.Experimental study:The plasma ET,NO,retinal SOD,MDA and Glu of the acute high intraocular pressure rats that treated with Yi Yin Ming Mu mixture were observed.2. Clinical study:The clinical therapeutic effect was observed by means of comparing the changes of visual acuity, visual field and intraocular pressure, before and after treatment.Results:1.Yi Yin Ming Mu mixture can effectively improve the activity of SOD, reduce the content of MDA, Glu, ET and NO of the acute high intraocular pressure rats.2. The curative effect of Yi Yin Ming Mu mixture in treatment of glaucoma in middle and advanced stage is obvious, with a total effective rate was 94.87%. Conclusion:l.The therapeutic effect of Yi Yin Ming Mu mixture in treatment of the patients with glaucoma in middle and advanced stage is identified.2.Yi Yin Ming Mu mixture can stablize the intraocular pressure and protect the optic nerve probably through clearing free radical, improving the anoxia tolerance, modifying microcirculation, restraining the releasing of Glu and reducing the content of ET.
Objective:To treat the glaucoma in middle and advanced stage with the method of YiQiYangYinKaiQiao and to study the mechanism of stabilizing the intraocular pressure and protecting the optic nerve with it.Methods:1.Experimental study:The plasma ET,NO,retinal SOD,MDA and Glu of the acute high intraocular pressure rats that treated with Yi Yin Ming Mu mixture were observed.2. Clinical study:The clinical therapeutic effect was observed by means of comparing the changes of visual acuity, visual field and intraocular pressure, before and after treatment.Results:1.Yi Yin Ming Mu mixture can effectively improve the activity of SOD, reduce the content of MDA, Glu, ET and NO of the acute high intraocular pressure rats.2. The curative effect of Yi Yin Ming Mu mixture in treatment of glaucoma in middle and advanced stage is obvious, with a total effective rate was 94.87%. Conclusion:l.The therapeutic effect of Yi Yin Ming Mu mixture in treatment of the patients with glaucoma in middle and advanced stage is identified.2.Yi Yin Ming Mu mixture can stablize the intraocular pressure and protect the optic nerve probably through clearing free radical, improving the anoxia tolerance, modifying microcirculation, restraining the releasing of Glu and reducing the content of ET.
引文
[1]葛坚.眼科学,北京：人民卫生出版社,2002：142.
[2]李美玉.青光眼药物治疗新概念.第九界全国眼科学术大会论文汇编,2004：32.
[3]Ben Simon GJ, Bakalash S, Aloni E, et al. A rat model for acute rise in intraocular pressure:immune modulation as a therapeutic strategy. Am J Ophthalmol,2006, 141:1105-1111.
[4]周文炳.临床青光眼,北京：人民卫生出版社,2000,2：189—201.
[5]陈耀真.谈子夏丧明.中华医学杂志,1938；(1)：35.
[6]王明杰.玄府论.成都中医学院学报,1985；(3)：1—4.
[7]王明杰.刘完素“玄府”说浅识.河北中医,1984；(4)：7—9.
[8]王明杰.专题笔谈.中医杂志,]989；(2)：70-71.
[9]李国新,卢奇志.眼科玄府学说的形成及其机理探讨.中国中医眼科杂志,1999；9(2)：105.
[10]金·刘完素.素问玄机原病式,北京：人民卫生出版社,1983,1：180.
[11]明·楼英.医学纲目,北京：人民卫生出版社,1987,1：430.
[12]明·傅仁宇.审视瑶函,沈阳：辽宁科学技术出版社,1997,1：15.
[13]清·马云从.眼科阐微,南京：江苏科技出版社,1984：5.
[14]陈达夫.中国眼科六经法要,成都：四川人民出版社,1978：72.
[15]成都中医学院编著.中医眼科学,北京：人民卫生出版社,1985：210.
[16]肖志正.刘河间玄府学说与眼病初探.中西医结合眼科,1983,2：1.
[17]廖品正.中医眼科学,上海：上海科学技术出版社,1986：104—110.
[18]常富业,王永炎,高颖,等.水淫玄府与隐性水肿假说.山东中医杂志,2004；23(11)：643—645.
[19]常富业,王永炎,高颖,等.论开通玄府.中国临床康复,2005；9(39)：128-129.
[20]张晓峰.老年人体质特点及用药规律考释.中医药学刊,2001；19(3)：238—239.
[21]宿艳.益气养阴开窍法在中晚期青光眼视神经保护中的应用[C].2006,4：1—27.
[22]王静波,陈美荣,李伯勤,等.益阴明目合剂对高眼压大鼠超微结构的影响.吉林 中医药,2008；28(1)：59-61.
[23]葛坚.眼科学,北京：人民卫生出版社,2002：166.
[24]胡熙明.中华本草,上海：上海科学技术出版社,1999：8.142.
[25]胡熙明.中华本草,上海：上海科学技术出版社,1999：8.125.
[26]胡熙明.中华本草,上海：上海科学技术出版社,1999：7.603.
[27]陈长勋.中药药理学,上海：上海科学技术出版社,2006：162.
[28]胡熙明.中华本草,上海：上海科学技术出版社,1999：7.267.
[29]马志茹,袁倬斌.电化学法研究枸杞子及黄精对活性氧自由基的清除作用.中国药学杂志,1999；34(10)：665—667.
[30]顾峥,陈道峰,胡天喜,等.戈米辛J对氧自由基的作用.上海医科大学学报,1999；26(5)：368—370.
[31]陈长勋.中药药理学,上海：上海科学技术出版社,2006：176.
[32]Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular Aspects in the Pathophysiology of Glaucomatous Optic Neuropathy.Survey of Opthalmology,1999; 43(suppl 1)June:s43-s50.
[33]郑虎占.中药现代研究与临床应用,北京：学苑出版社,1997：1363.
[34]冯亚,杜炳辉,吴作干,等.行气祛痰化浊中药对血小板聚集性、红细胞变形性及血液粘度作用初探.福建中医学院学报,1998；8(1)：24.
[35]郑虎占.中药现代研究与临床应用,北京：学苑出版社,1997：4073.
[36]周旋,王颖,包晓玮,等.新疆枸杞多糖抗实验性衰老及自然衰老的研究.西北药学杂志,2009；24(1)：29.
[37]胡熙明.中华本草,上海：上海科学技术出版社,1999：5.893.
[38]葛坚.眼科学,北京：人民卫生出版社,2002：165.
[39]韩桂茹,贺秀芬,杨建红,等.党参化学成分的研究.中国中药杂志,1990；15(2)：105.
[40]Wan M P,et al.Planta Med,1983,49 (1):60.
[41]余伯阳,徐国钧,金蓉鸾,等.麦冬类中药的药源调查和商品鉴定.中国药科大学学报,1991；22(5)：286.
[42]黄九龄,李晓玲.五味子缩瞳收泪拾偶.实用中医药杂志,1997；2：26.
[43]唐由之,肖国士.中医眼科全书,北京：人民卫生出版社,1996：1121—1122.
[44]胡熙明.中华本草,上海：上海科学技术出版社,1999：8.472.
[45]陈长勋.中药药理学,上海：上海科学技术出版社,2006：144.
[46]易宁育,夏宗勤,胡雅儿,等.滋阴、助阳药对β肾上腺素受体及M胆碱受体的双向调节作用.中医杂志,1989；10：44—46.
[47]沈映君.中药药理学,北京：人民卫生出版社,2000：14.
[48]Neville N. Osborne, Glyn Chidlow, et al.The potential of neuroprotection in glaucoma treatment.Current Opinion in Ophthalmology,1999,10:82.
[49]Caprioli J.Neuroprotection of the optic nerve in glaucoma.Acta Ophthalmol,1994, 75:364.
[50]Yoles E, Schwartz M.Potential neuroprotective therapy for glaucomatous optic neuropathy.Surv Ophthalmol,1998,42:367.
[51]葛坚,郭彦.青光眼视神经损伤与视神经保护.食品与药,2005；7(5A)：17—23.
[52]王艳,孙兴怀.青光眼视神经保护治疗的实验研究.眼科新进展,2002；22(3)：212—215.
[53]KitazawalY, Shirai H, Go FJ. The effect of Ca2+-antagonist on visual field in low-tension glaucoma.Graefes Arch Clin Exp Ophthalmol,1989; 227:408.
[54]Netland PA, Chaturvedi N, Dreye EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma.Am J Ophthalmol,1993; 115:608.
[55]Bose S, Piltz JR, Breton ME. Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma and in control subjects.Ophthalmology,1995; 102(8):1236.
[56]Piltz JR, Bose S, Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects.J Glaucoma,1998; 7(5):336.
[57]Toriu N, Akaike A, Yasuyoshi H, Zhang S, Kashii S, Honda Y,et al. Lomerizine, a Ca2+channel blocker, reduces glutamate-induced neurotoxicity and ischemia/ reperfusion damage in rat retina.Exp Eye Res,2000; 70(4):475.
[58]Morgan J, Caprioli J, Koseki Y. Nitric oxide mediates excitotoxic and anoxic damage in rat retinal ganglion cells cocultured with astroglia.Arch Ophthalmol,1999; 117(11):1524.
[59]Heiduschka P, Thanos S. Aurintricarboxylic acid promotes survival and regeneration of axotomised retinal ganglion cells in vivo.Neurop harmacology,2000; 39(5):889.
[60]Freeman EE, Grosskreutz CL. The effects of FK506 on retinal ganglion cells after optic nerve crush.Invest Ophthalmol Vis Sci,2000; 41(5):1111.
[61]Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells.JNeurosci,2000; 20(23):8693.
[62]Yongping Li, Jian Ge,et al. Differentiation of embryonic stem cells into neurons and retina-like structure in nude mice.Eye Science,1999; 15(3):131.
[63]郭彦,葛坚.体外定向诱导胚胎干细胞ES-D3细胞系分化为神经细胞初步研究.第十一届临床眼科学学术会议,1999；4.
[64]David S& Aguayo AI:Axonal elongation into peripheral system'bridges'after central neurons systerm injury in adult rats.Science,1981; 20,214(4523):931.
[65]Richardson PM et al.Axons from central nervous system regenerate into peripheral nervous systan graft. Nature,1980; 284:264.
[66]Zacco A, et al.Isolation, biochemical characterization and ultrastrucrural analysis of the limbic system associated membrane protein (LAMP), a protein expressed by neuron comprising functional neural circuits. J Neurosci,1990; 10:73.
[67]Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, et al.Production of neurotrophins by activated T cells:implications for neuroprotective autoimmunity.J Autoimmun,2000; 15(3):331.
[68]Cage FH, et al.Genetically modified cells:applications for intraoerebral grafting. Trends Neuroses,1991; 14:328.
[69]Lucidi Phillpi CA, et al.BDNF—transduced fibroblasts:production of BDNF and grafting to adult rat brain. J Comp Neuxd,1995; 354:361.
[70]Okisaka S, Murakami A, Mizukawa A, et al. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes.Jpn J Ophthalmol,1997,41(2):84-88.
[71]Kerrigan LA, Zack DJ, Quigley HA, et al.TUNEL—positive ganglion cells in human primary open—angle glaucoma. Arch Ophthalmol,1997; 115(8):1031-1035.
[72]Ward MM, Job ling Al, Puthussery T, et al. Localization and expression of the glutamate transporter, excitatory am in acid transporter 4 with in astrocytes of the rat retina.Cell Tissue Res,2004; 315(3):305-310.
[73]Atalla A, Kusch insky K, Effects of blockade of glutam ate NMDA receptors or NO synthase on the development or the expression of associative or non-associative sensitization to locomotor activation by morphine.Neural Transm,2006; 113(1):1-10.
[74]Dreyer E B, Zurakowsk iD, Schumer R A, et al.Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma.ArchOphthalmol,1996, 114(3):299-305.
[75]Nickells, RW.Retinal ganglion cell death in glaucoma:the how, the why, and the maybe.J Glaucoma,1996; 5(5):345-356.
[76]Smith DS. Barbiturates as free radical scavengers and protective agents in brain ischemia.In Johnson JE, et al. (Eds)Free radical, Aging, Degenerative disease.Alan R.Liss, Inc, New york,1986:457.
[77]徐度.自由基生物学与眼组织损伤的病理机理.国外医学眼科分册,1987；11：16.
[78]赵海霞,Jean Pierre KOLB中国留学生生物学会96年度交流会汇编,1996；11.
[79]Shareef S, et al.Invest Ophthalmol Vis Sci,1999; 40:2884-2891.
[80]Neufeld AH, et al.Arch Ophthalmol,1997; 115:497-503.
[81]Geyer O, Almog J, Lupu MM, et al.Nitricoxide synthase inhibitors protect rat retina against ischemic injury.FEBS-Sett,1995; 374:399-405.
[82]薛蔚,杜蜀华,李勇,等.压力对牛眼小梁细胞诱导型—氧化氮合酶mRNA的表达及蛋白质合成的影响.中华眼科杂志,2000；36(4)：295—298.
[83]Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol,1997; 115::497-503.
[84]路雪婧.DXY对持续性高眼压大鼠模型视网膜神经节细胞损害的干预及机理研究[C].2003,4：24.
[85]黄家兰.川芎嗪穴位注射对兔慢性高眼压视网膜保护作用的实验研究[C].2006,5：9.
[86]Macumber MW, Jampel HD, Synder SH, Ocular effects of the endothelins:abundant peptide in the eye.Arch Ophthalmol,1991; 109:705-709.
[87]Sugiyama T, Moriya S, Oku H, Azumma I, Association of endothelin-1 with normal tension glaucoma:clinical and fundamental studies.Surv Opthalmol,1995;39 Suppl 1:S49-S56.
[88]Sugiyama K, Haque MSR, Okada K, Taniguchi T, Kitazawa Y, Intraocular pressure response to injection of endothelin-1 and the mediatory role of ETA and ETB receptor, and cyclooxygenase products in rabbits[J]. Curr Eye Res,1995; 14:479-486.
[89]Haque MSR, Sugiyama K, Taniguchi T, Kitazawa Y. Effects of BQ-123, and ETA receptor selective antagonist, onchanges of intraocular pressure, blood-aqueous barrier and aqueous prostaglandin concentrations caused by endothelin-1in rabbit[J].Jpn J Ophthalmol,1996; 40:26232.
[90]Taniquchi T, Haque MSR, Sugiyama K, Okada K, Nakai Y, Kitazawa Y. Effects of endothelin A and B receptors on aqueous humor dynamics in the rabbit eye[J]. J Ocular Pharmacol Ther,1996; 123-130.
[91]Erickson-Lamy K, Korbmacher C, Schuman JS, Nathanson JA. Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo [J]. Invest Ophthalmol Vis Sci,1991; 32:492-495.
[92]Erickson-Lamy K, Korbmacher C, Schuman JS, Nathanson JA. Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo [J]. Invest Ophthalmol Vis Sci,1991; 32:492-495.
[93]Yousufzai SY, Abdel-latif AA. Endothelin-1 stimulates the release of arachidonic acid and prostaglandins in cultured human ciliary muscle cells:activation of phospholipase A2, Exp Eye Res,1997;,65(1):73-81.
[94]Haefliger IO, Flammer J, Lucher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery [J]. Invest Ophhthalmol Vis Sci,1992; 33:2340-2343.
[95]Oku H, Sugiyama T, Moriya S, Hamada J, Azuma I. Effects of inravitreal injection of endothelin on the visual system[J].J JpnOphthalmolSoc,1993; 97:467-473.
[96]Azuma I. Progress inmedical treatment of glaucoma [J]. J Jpn Ophthalmol Soc,1993; 97:1353-1369.
[97]Cioffi GA, Sullivan P. The effect of chronic ischema on the primate optic nerve. Eur J Ophthamol,1999; 9(suppl 1):s34-36.
[98]Cioffi GA, Wang L, Fortune B, et al. Chronic ischemia induces regional axonal damage in experimental primate optic neuropathy. Arch Ophthalmol,2004; 122(10):1517-1525.
[99]Cioffi GA, Sullivan P. The effect of chronicis chemia on the primate optic nerve [J]. Eur J Ophthalmol,1999; 9(suppl1):3436.
[100]Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol, 1998; 32(supPl3):s2-s13.
[101]Luscher TF, Vanhoutte PM. The endothelin:Modulator of cardiovascular function. Boca Raton, FL:CRC Press.1990; 1-228.
[102]Kim TW, Kang KB, Choung HK, et al. Elevated glutamate levels in the vitreous body of an vivo model of optic nerve ischemia. Arch Ophthalmol,2000,118(4):533 —536.
[103]Stokely ME, Brady ST, Yorio T. Effects of endothelin-1 on components of anterograde axonal transport in optic nerve. Invest Ophthalmol Vis Sci,2002; 43(10):3223-3230.
[104]Hernandez MR. The optic nerve head in glaucoma:Role of astrocytes in tissue remodeling. Prog Retin Eye Res,2000; 19(3):297-321.
[105]Prasanna G, Krishnamoorthy R, Clark AF, et al. Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci,2002; 43(8):2704-2713.
[106]蔡维,徐克勤,李国保.原发性开青患者房水内皮素的检测.临床眼科杂志,2000；8(6)：424—425.
[107]魏敏,符本琪,王延俊,等.原发性开角型青光眼房水内皮素与眼压的相关关系研究.临床眼科杂志,2000;8(5)：344—345.
[108]岑志敏,张庆平.内皮素—1与青光眼视神经损害.广西医学,2005；27(7)：1040—1042.
[109]郑晓光,杨新光,王为农,等.血液中一氧化氮和内皮素与开青的关系.眼科研究,2001；19(3)：269-270.
[110]严灿荣,梁轩伟.青光眼视功能损害中内皮素—1的作用及其机制.中国临床康复,2005；9(14)：156—157.
[111]彭清华,朱文锋,李传课,等.原发性闭角型青光眼患者血浆内皮素改变与中医证型关系的研究.中国中医眼科杂志,2000；10(4)：207—210.
[112]傅东红,王安悦.急性闭角型青光眼血浆内皮素-1水平的变化.眼科新进展,2002；22(6)：408—409.
[113]李志辉.青光眼,北京：北京科学技术出版社,1999：28—33.
[114]周文炳.临床青光眼,北京：人民卫生出版社,2000,2：60—62.
[115]佘华宁,王蔼青.啤酒降低眼压的临床观察.陕西医学杂志,1995；11(24)：671—672.
[116]Shields MB.Textbook of glaucoma.3rded.Baltimore:Williams&Wilkins,1992:45-75.
[117]李汶霞,李清美,王志新,等.缺血性脑血管病患者血浆内皮素水平昼夜节律变化的研究.微循环学杂志,1998；8(2)：20—22.
[118]林允信,刘允泰,王育敏,等.肺心病急性期动、静脉血浆内皮素-1昼夜含量比较.中华内科杂志,1994；33(10)：696.
[119]Young MW, Jackson FR, Shin HS, et al.A biological clock in drosophila. Cold Spring Harbor Symp Quent Biol,1985; 50:865-875.
[120]Simonson MS, Dunn MJ. Endothelins, A family of regulatory pep-tides. Hyperten-sion,1991; 6:856-863.
[121]ElherikK, KhanF, McLarenM, etal.Circadian variation invascular tone and endoth-elial cell functioninnor malmales.Clin Sci,2002; 102:547-552.
[1]葛坚.眼科学,北京：人民卫生出版社,2002：142.
[2]Neville N. Osborne, Glyn Chidlow, et al. The potential of neuroprotection in glaucoma treatment. Cur-rent Opinion in Ophthalmology,1999,10:82.
[3]Caprioli J. Neuroprotection of the optic nerve in glaucoma. Acta Ophthalmol,1994, 75:364.
[4]Yoles E, Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthal-mol,1998,42:367.
[5]Nickells RW. Retinal ganglion cell death in glaucoma:the how, the why and the maybe.J Glaucoma,1996,5:345.
[6]Mckinnon SJ:Glaucoma, appoptosis and neuroprotection. Curr Opin Ophthalmol, 1997,8:28.
[7]Otori Y, Wei JY, Bamstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci,1998,39:972.
[8]Ge Jian, Wenbing Zhou.et al. The study of relationships among the damage of visual function and hemorrheology, ocular rheography, and other influencing factors in glaucomatous patients. Eye Science,1993,9(1):3.
[9]葛坚.青光眼与神经细胞诱向因子.眼科学报,1997；13(2)：100.
[10]吴永青,葛坚.视网膜神经节细胞培养、纯化及生物学特性研究.中华眼科杂志,1999；35(3)：190.
[11]葛坚,吴永青.N-甲基天门冬氨酸和地塞米松对体外培养鼠视网膜神经节细胞凋亡作用观察.眼科学报,1999；15(2)：65.
[12]Oku H, et al. Surv Ophthalmol,1999,44(Suppl):S74.
[13]Neufeld AH,et al.Proc Natl Acad Sci USA,1999,96:9944.
[14]Dreyer EB,et al.J Glaucoma,1998,7:62.
[15]Osborne N, et al. Surv Ophthalmol,1999,43(Suppl):102.
[16]Levin LA,Schlamp CL,Spieldoch RL.et al. Identification of the bcl-2 family of genes in the rat retina.Invest Ophthalmol Vis Sci.1997,38:2545.
[17]Biose LH, Thompson CB. Bcl-xl can inhibit apoptosisin cells that have undergone Fas-induced protease activation.Proc Natl Acad Sci USA.1997,94:3759.
[18]谷雄霜,方爱武,谢丛森.中西医结合治疗晚期青光眼临床分析.中国中医眼科杂志,1996；6(4)：225.
[19]秦大军,祝素英.中药在青光眼术后的作用观察.中国中医眼科杂志,1997；7(3):184.
[20]毕留彬,毕泗松.杞菊地黄汤对原发性开角型青光眼术后增视效果的观察.中西医结合眼科杂志,1996；14(4)：240.
[21]张晓辉.通窍明目汤对原发性闭角型青光眼术后视神经保护作用的临床研究[C].2005.5：1—37.
[22]王万杰,周华祥,缪馨.王明芳教授治疗青光眼围手术期的经验.成都中医药大学学报,2007；30(4)：18.
[23]刘芳琼,龚华,刘照耀,等.石斛夜光丸加减治疗晚期青光眼术后28例总结.湖南中医杂志,2005；21(4)：22.
[24]代明山,阿拉坦图雅.蒙药治疗术后晚期青光眼.中医药学刊,2005；23(10)：1918.
[25]王静波,陈美荣,李伯勤,等.益阴明目合剂对高眼压大鼠超微结构的影响.吉林中医药,2008；28(1)：59-61.
[26]宿艳.益气养阴开窍法在中晚期青光眼视神经保护中的应用[C].2006,4：1—27.
[27]周峻,钱爱华.川芎嗪穴位注射对青光眼术后视功能保护的临床观察.湖北中医杂志,2007;29(7)：33—34.
[28]夏勇.关于针刺改善青光眼视功能损害机理的研究进展.河南中医学院学报,,2006；21(2)：87-88.
[29]周金黄.中药药理学,上海：上海科学出版社,1985：190—192.
[30]陈可冀,张之南,梁子钧,等.中西医结合研究丛书,上海：上海科学技术出版社,1990：509—523.
[31]李公宝,郭宝强.四甲基吡嗪抗血小板活性及抗栓治疗.中国微循环杂志,1997；5：110—112.
[32]施月欢,邹秀兰.川芎嗪对大鼠缺血再灌注视网膜SOD.MDA和NO水平及细胞凋亡的影响.中国实用眼科杂志,2002；20(1)：25.
[33]宋宗明,崔守信,张得秀.川芎嗪对兔眼高压下的视网膜神经节细胞和双极细胞损伤的保护作用.第四军医大学学报,2001；22(6)：514—516.
[34]刘杏,周文炳,葛坚,等.中药川芎嗪治疗原发性开角性青光眼视功能损害的疗效.中国实用眼科杂志,1999；17(1)：14.
[35]贺玉红,周樱.川芎嗪联合弥可保对晚期青光眼术后增视疗效观察.中国医药导报,2008；5(24)：207.
[36]李兴英,李公宝,杨连洲.原发性开角型青光眼微循环改变及临床意义.中国微循环杂志,1998；2：168—170.
[37]李兴英,杨连洲,康凤英,等.川芎嗪对兔高眼压视神经轴突损伤保护作用的研究.中华眼科杂志,2000；36(6)：442—444.
[38]葛坚.青光眼视功能损害与血液流变学、眼血流图及其它诸影响因素相互关系的研究.中华眼科杂志,1992；28(4)：195.
[39]吕世荣,王桂荣,佟琪,等.原发性开角型青光眼的血液流变学测定.眼科研究,1992；10：(4)：257—259.
[40]李钟秀,史蕙苓,陈程,等.原发性青光眼血浆血管紧张素Ⅱ测定的初步报告.眼科研究,1993；11(1)：38—39.
[41]李国彦.青光眼的现代诊疗,武汉：湖北科学技术出版社,1990,1：34—85.
[42]彭清华,朱惠安,李伟力.增视Ⅰ号治疗抗青光眼手术后患者114例的临床观察.中国医药学报.1994：9(3)：25—26.
[43]彭清华,罗萍,李传课,等.青光安颗粒对青光眼术后患者作用的临床研究.中国中医眼科杂志,1997；7(3)：151—155.
[44]彭清华,李建超.青光安治疗抗青光眼术后患者临床研究.湖南中医学院学报.2004；24(2)：36—39.
[45]郭跃侠,吴惠群,雷嘉启.葛根素治疗青光眼的研究现状与展望.中国中医眼科杂志,2002；12(2)：182—184.
[46]吴正红,刘有潜,朱延勤,等.葛根素滴眼液对家兔眼内压的作用.中国药科大学学报,1998；29(5)：387—389.
[47]王昌鹏,杨新光,王晓娟.几种中药对青光眼视网膜节细胞的保护作用.中国实用眼科杂志,2004；22(3)：164—166.
[48]张敏,张秋玲,叶润才.中西医结合改善晚期青光眼术后视功能的疗效观察.新中医,2005；37(6)：58—59.
[49]杜宁静,陈琦.复方丹参滴丸对闭角型青光眼患者红细胞免疫功能的影响.眼科研究,2003；21(3)：312.
[50]秦大军,张义平.复方丹参液对晚期青光眼术后增视作用的临床研究.中西医结合眼科杂志,1998；16(2):74.
[51]张人伟.灯盏花黄酮类成分的分离鉴定.中草药,1988；19：7.
[52]蒋幼芹,吴振中,莫杏君.眼压已控制的晚期青光眼治疗的探讨.眼科研究,1991；9(4)：229—232.
[53]罗旭异,高健生.中医眼科围手术期治疗的现状与展望.中国中医眼科杂志,2001； 11 (2)：118.
[54]陈明英,中医药在青光眼手术前后的应用体会.河南中医,200；26(9)：31
[55]方国新.顽固性青光眼术前毫针前房穿刺降压效果.中医医结合眼科杂志,1996；14(4)：241.
[56]胡玉春.针灸治疗急性闭角型青光眼.中医医结合眼科杂志,1995；13(4):258.
[57]秦大军,祝素英.中药在青光眼术后的作用观察.中国中医眼科杂志,1997；7(3)：184.
[58]付晓民.白内障及青光眼术后应用三七胶囊疗效观察.中国中医眼科杂志,1997；7(2)：115.
[59]韩红波,柏超然.青光眼滤过术后前房积血的中西医结合治疗和原因分析.中国中医眼科杂志,2001；11(3)：162—163.
[60]姜道平,魏鸿友,董玉根.中西医结合治疗青光眼术后反应.中西医结合眼科杂志,1997；15(2)：85—86.
[61]韩其江,李智敏.活血化瘀法治疗急性充血性青光眼术后反应.中西医结合眼科杂志,1994；12(3)：181.
[62]陈明英,中医药在青光眼手术前后的应用体会.河南中医,2006；26(9)：31.
[63]石守礼.泻肝解郁汤加减治疗青光眼.新中医,1986；10：31.
[64]汤爱灿.中医西结合治疗滤过性抗青光眼术后前房迟缓形成的疗效观察.海南医学,2001；12(4)：44.
[65]许晓平,崔艳红,沈玲,等.泻肝利水法治疗滤过性手术后前房延缓形成临床观察.中国中医眼科杂志,1997；7(1)：45.
[66]郑恕远,杜志山,杨万期.八珍汤合五苓散加减治疗滤过性抗青光眼术后前房迟延形成临床观察.中国中医眼科杂志,1995；5(1)：32.
[67]王建君,龚时贤.青光眼滤过术后浅前房的中西医结合治疗.浙江临床医学,2002；4(3)：197.
[68]陈瑛,陈金华.中西医结合治疗青光眼滤过术后浅前房.浙江中西医结合杂志,2000；10(3)：171.
[69]杨树立,张坤丽,张凤英,等.中西医结合治疗青光眼晚期浅／无前房.中西医结合眼科杂志,1995；13(3)：133—134.
[70]杨海燕.补阳还五汤治疗滤过性手术后前房延缓形成临床观察.中国中医眼科杂 志,1999；9(1)：39.
[71]陈静琪,余晓临,杨国华.综合治疗青光眼术后前房延缓形成.中国中医眼科杂志,1994：4(1)：18.
[72]张玲,马小丽.青光眼术后低眼压综合征的中医治疗.北京中医,2006；25(3)：161—162.
[73]葛坚,孙兴怀,王宁利.现代青光眼研究进展,南京：江苏科学技术出版社,2000：68—70.
[2]李美玉.青光眼药物治疗新概念.第九界全国眼科学术大会论文汇编,2004：32.
[3]Ben Simon GJ, Bakalash S, Aloni E, et al. A rat model for acute rise in intraocular pressure:immune modulation as a therapeutic strategy. Am J Ophthalmol,2006, 141:1105-1111.
[4]周文炳.临床青光眼,北京：人民卫生出版社,2000,2：189—201.
[5]陈耀真.谈子夏丧明.中华医学杂志,1938；(1)：35.
[6]王明杰.玄府论.成都中医学院学报,1985；(3)：1—4.
[7]王明杰.刘完素“玄府”说浅识.河北中医,1984；(4)：7—9.
[8]王明杰.专题笔谈.中医杂志,]989；(2)：70-71.
[9]李国新,卢奇志.眼科玄府学说的形成及其机理探讨.中国中医眼科杂志,1999；9(2)：105.
[10]金·刘完素.素问玄机原病式,北京：人民卫生出版社,1983,1：180.
[11]明·楼英.医学纲目,北京：人民卫生出版社,1987,1：430.
[12]明·傅仁宇.审视瑶函,沈阳：辽宁科学技术出版社,1997,1：15.
[13]清·马云从.眼科阐微,南京：江苏科技出版社,1984：5.
[14]陈达夫.中国眼科六经法要,成都：四川人民出版社,1978：72.
[15]成都中医学院编著.中医眼科学,北京：人民卫生出版社,1985：210.
[16]肖志正.刘河间玄府学说与眼病初探.中西医结合眼科,1983,2：1.
[17]廖品正.中医眼科学,上海：上海科学技术出版社,1986：104—110.
[18]常富业,王永炎,高颖,等.水淫玄府与隐性水肿假说.山东中医杂志,2004；23(11)：643—645.
[19]常富业,王永炎,高颖,等.论开通玄府.中国临床康复,2005；9(39)：128-129.
[20]张晓峰.老年人体质特点及用药规律考释.中医药学刊,2001；19(3)：238—239.
[21]宿艳.益气养阴开窍法在中晚期青光眼视神经保护中的应用[C].2006,4：1—27.
[22]王静波,陈美荣,李伯勤,等.益阴明目合剂对高眼压大鼠超微结构的影响.吉林 中医药,2008；28(1)：59-61.
[23]葛坚.眼科学,北京：人民卫生出版社,2002：166.
[24]胡熙明.中华本草,上海：上海科学技术出版社,1999：8.142.
[25]胡熙明.中华本草,上海：上海科学技术出版社,1999：8.125.
[26]胡熙明.中华本草,上海：上海科学技术出版社,1999：7.603.
[27]陈长勋.中药药理学,上海：上海科学技术出版社,2006：162.
[28]胡熙明.中华本草,上海：上海科学技术出版社,1999：7.267.
[29]马志茹,袁倬斌.电化学法研究枸杞子及黄精对活性氧自由基的清除作用.中国药学杂志,1999；34(10)：665—667.
[30]顾峥,陈道峰,胡天喜,等.戈米辛J对氧自由基的作用.上海医科大学学报,1999；26(5)：368—370.
[31]陈长勋.中药药理学,上海：上海科学技术出版社,2006：176.
[32]Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular Aspects in the Pathophysiology of Glaucomatous Optic Neuropathy.Survey of Opthalmology,1999; 43(suppl 1)June:s43-s50.
[33]郑虎占.中药现代研究与临床应用,北京：学苑出版社,1997：1363.
[34]冯亚,杜炳辉,吴作干,等.行气祛痰化浊中药对血小板聚集性、红细胞变形性及血液粘度作用初探.福建中医学院学报,1998；8(1)：24.
[35]郑虎占.中药现代研究与临床应用,北京：学苑出版社,1997：4073.
[36]周旋,王颖,包晓玮,等.新疆枸杞多糖抗实验性衰老及自然衰老的研究.西北药学杂志,2009；24(1)：29.
[37]胡熙明.中华本草,上海：上海科学技术出版社,1999：5.893.
[38]葛坚.眼科学,北京：人民卫生出版社,2002：165.
[39]韩桂茹,贺秀芬,杨建红,等.党参化学成分的研究.中国中药杂志,1990；15(2)：105.
[40]Wan M P,et al.Planta Med,1983,49 (1):60.
[41]余伯阳,徐国钧,金蓉鸾,等.麦冬类中药的药源调查和商品鉴定.中国药科大学学报,1991；22(5)：286.
[42]黄九龄,李晓玲.五味子缩瞳收泪拾偶.实用中医药杂志,1997；2：26.
[43]唐由之,肖国士.中医眼科全书,北京：人民卫生出版社,1996：1121—1122.
[44]胡熙明.中华本草,上海：上海科学技术出版社,1999：8.472.
[45]陈长勋.中药药理学,上海：上海科学技术出版社,2006：144.
[46]易宁育,夏宗勤,胡雅儿,等.滋阴、助阳药对β肾上腺素受体及M胆碱受体的双向调节作用.中医杂志,1989；10：44—46.
[47]沈映君.中药药理学,北京：人民卫生出版社,2000：14.
[48]Neville N. Osborne, Glyn Chidlow, et al.The potential of neuroprotection in glaucoma treatment.Current Opinion in Ophthalmology,1999,10:82.
[49]Caprioli J.Neuroprotection of the optic nerve in glaucoma.Acta Ophthalmol,1994, 75:364.
[50]Yoles E, Schwartz M.Potential neuroprotective therapy for glaucomatous optic neuropathy.Surv Ophthalmol,1998,42:367.
[51]葛坚,郭彦.青光眼视神经损伤与视神经保护.食品与药,2005；7(5A)：17—23.
[52]王艳,孙兴怀.青光眼视神经保护治疗的实验研究.眼科新进展,2002；22(3)：212—215.
[53]KitazawalY, Shirai H, Go FJ. The effect of Ca2+-antagonist on visual field in low-tension glaucoma.Graefes Arch Clin Exp Ophthalmol,1989; 227:408.
[54]Netland PA, Chaturvedi N, Dreye EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma.Am J Ophthalmol,1993; 115:608.
[55]Bose S, Piltz JR, Breton ME. Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma and in control subjects.Ophthalmology,1995; 102(8):1236.
[56]Piltz JR, Bose S, Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects.J Glaucoma,1998; 7(5):336.
[57]Toriu N, Akaike A, Yasuyoshi H, Zhang S, Kashii S, Honda Y,et al. Lomerizine, a Ca2+channel blocker, reduces glutamate-induced neurotoxicity and ischemia/ reperfusion damage in rat retina.Exp Eye Res,2000; 70(4):475.
[58]Morgan J, Caprioli J, Koseki Y. Nitric oxide mediates excitotoxic and anoxic damage in rat retinal ganglion cells cocultured with astroglia.Arch Ophthalmol,1999; 117(11):1524.
[59]Heiduschka P, Thanos S. Aurintricarboxylic acid promotes survival and regeneration of axotomised retinal ganglion cells in vivo.Neurop harmacology,2000; 39(5):889.
[60]Freeman EE, Grosskreutz CL. The effects of FK506 on retinal ganglion cells after optic nerve crush.Invest Ophthalmol Vis Sci,2000; 41(5):1111.
[61]Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells.JNeurosci,2000; 20(23):8693.
[62]Yongping Li, Jian Ge,et al. Differentiation of embryonic stem cells into neurons and retina-like structure in nude mice.Eye Science,1999; 15(3):131.
[63]郭彦,葛坚.体外定向诱导胚胎干细胞ES-D3细胞系分化为神经细胞初步研究.第十一届临床眼科学学术会议,1999；4.
[64]David S& Aguayo AI:Axonal elongation into peripheral system'bridges'after central neurons systerm injury in adult rats.Science,1981; 20,214(4523):931.
[65]Richardson PM et al.Axons from central nervous system regenerate into peripheral nervous systan graft. Nature,1980; 284:264.
[66]Zacco A, et al.Isolation, biochemical characterization and ultrastrucrural analysis of the limbic system associated membrane protein (LAMP), a protein expressed by neuron comprising functional neural circuits. J Neurosci,1990; 10:73.
[67]Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, et al.Production of neurotrophins by activated T cells:implications for neuroprotective autoimmunity.J Autoimmun,2000; 15(3):331.
[68]Cage FH, et al.Genetically modified cells:applications for intraoerebral grafting. Trends Neuroses,1991; 14:328.
[69]Lucidi Phillpi CA, et al.BDNF—transduced fibroblasts:production of BDNF and grafting to adult rat brain. J Comp Neuxd,1995; 354:361.
[70]Okisaka S, Murakami A, Mizukawa A, et al. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes.Jpn J Ophthalmol,1997,41(2):84-88.
[71]Kerrigan LA, Zack DJ, Quigley HA, et al.TUNEL—positive ganglion cells in human primary open—angle glaucoma. Arch Ophthalmol,1997; 115(8):1031-1035.
[72]Ward MM, Job ling Al, Puthussery T, et al. Localization and expression of the glutamate transporter, excitatory am in acid transporter 4 with in astrocytes of the rat retina.Cell Tissue Res,2004; 315(3):305-310.
[73]Atalla A, Kusch insky K, Effects of blockade of glutam ate NMDA receptors or NO synthase on the development or the expression of associative or non-associative sensitization to locomotor activation by morphine.Neural Transm,2006; 113(1):1-10.
[74]Dreyer E B, Zurakowsk iD, Schumer R A, et al.Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma.ArchOphthalmol,1996, 114(3):299-305.
[75]Nickells, RW.Retinal ganglion cell death in glaucoma:the how, the why, and the maybe.J Glaucoma,1996; 5(5):345-356.
[76]Smith DS. Barbiturates as free radical scavengers and protective agents in brain ischemia.In Johnson JE, et al. (Eds)Free radical, Aging, Degenerative disease.Alan R.Liss, Inc, New york,1986:457.
[77]徐度.自由基生物学与眼组织损伤的病理机理.国外医学眼科分册,1987；11：16.
[78]赵海霞,Jean Pierre KOLB中国留学生生物学会96年度交流会汇编,1996；11.
[79]Shareef S, et al.Invest Ophthalmol Vis Sci,1999; 40:2884-2891.
[80]Neufeld AH, et al.Arch Ophthalmol,1997; 115:497-503.
[81]Geyer O, Almog J, Lupu MM, et al.Nitricoxide synthase inhibitors protect rat retina against ischemic injury.FEBS-Sett,1995; 374:399-405.
[82]薛蔚,杜蜀华,李勇,等.压力对牛眼小梁细胞诱导型—氧化氮合酶mRNA的表达及蛋白质合成的影响.中华眼科杂志,2000；36(4)：295—298.
[83]Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol,1997; 115::497-503.
[84]路雪婧.DXY对持续性高眼压大鼠模型视网膜神经节细胞损害的干预及机理研究[C].2003,4：24.
[85]黄家兰.川芎嗪穴位注射对兔慢性高眼压视网膜保护作用的实验研究[C].2006,5：9.
[86]Macumber MW, Jampel HD, Synder SH, Ocular effects of the endothelins:abundant peptide in the eye.Arch Ophthalmol,1991; 109:705-709.
[87]Sugiyama T, Moriya S, Oku H, Azumma I, Association of endothelin-1 with normal tension glaucoma:clinical and fundamental studies.Surv Opthalmol,1995;39 Suppl 1:S49-S56.
[88]Sugiyama K, Haque MSR, Okada K, Taniguchi T, Kitazawa Y, Intraocular pressure response to injection of endothelin-1 and the mediatory role of ETA and ETB receptor, and cyclooxygenase products in rabbits[J]. Curr Eye Res,1995; 14:479-486.
[89]Haque MSR, Sugiyama K, Taniguchi T, Kitazawa Y. Effects of BQ-123, and ETA receptor selective antagonist, onchanges of intraocular pressure, blood-aqueous barrier and aqueous prostaglandin concentrations caused by endothelin-1in rabbit[J].Jpn J Ophthalmol,1996; 40:26232.
[90]Taniquchi T, Haque MSR, Sugiyama K, Okada K, Nakai Y, Kitazawa Y. Effects of endothelin A and B receptors on aqueous humor dynamics in the rabbit eye[J]. J Ocular Pharmacol Ther,1996; 123-130.
[91]Erickson-Lamy K, Korbmacher C, Schuman JS, Nathanson JA. Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo [J]. Invest Ophthalmol Vis Sci,1991; 32:492-495.
[92]Erickson-Lamy K, Korbmacher C, Schuman JS, Nathanson JA. Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo [J]. Invest Ophthalmol Vis Sci,1991; 32:492-495.
[93]Yousufzai SY, Abdel-latif AA. Endothelin-1 stimulates the release of arachidonic acid and prostaglandins in cultured human ciliary muscle cells:activation of phospholipase A2, Exp Eye Res,1997;,65(1):73-81.
[94]Haefliger IO, Flammer J, Lucher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery [J]. Invest Ophhthalmol Vis Sci,1992; 33:2340-2343.
[95]Oku H, Sugiyama T, Moriya S, Hamada J, Azuma I. Effects of inravitreal injection of endothelin on the visual system[J].J JpnOphthalmolSoc,1993; 97:467-473.
[96]Azuma I. Progress inmedical treatment of glaucoma [J]. J Jpn Ophthalmol Soc,1993; 97:1353-1369.
[97]Cioffi GA, Sullivan P. The effect of chronic ischema on the primate optic nerve. Eur J Ophthamol,1999; 9(suppl 1):s34-36.
[98]Cioffi GA, Wang L, Fortune B, et al. Chronic ischemia induces regional axonal damage in experimental primate optic neuropathy. Arch Ophthalmol,2004; 122(10):1517-1525.
[99]Cioffi GA, Sullivan P. The effect of chronicis chemia on the primate optic nerve [J]. Eur J Ophthalmol,1999; 9(suppl1):3436.
[100]Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol, 1998; 32(supPl3):s2-s13.
[101]Luscher TF, Vanhoutte PM. The endothelin:Modulator of cardiovascular function. Boca Raton, FL:CRC Press.1990; 1-228.
[102]Kim TW, Kang KB, Choung HK, et al. Elevated glutamate levels in the vitreous body of an vivo model of optic nerve ischemia. Arch Ophthalmol,2000,118(4):533 —536.
[103]Stokely ME, Brady ST, Yorio T. Effects of endothelin-1 on components of anterograde axonal transport in optic nerve. Invest Ophthalmol Vis Sci,2002; 43(10):3223-3230.
[104]Hernandez MR. The optic nerve head in glaucoma:Role of astrocytes in tissue remodeling. Prog Retin Eye Res,2000; 19(3):297-321.
[105]Prasanna G, Krishnamoorthy R, Clark AF, et al. Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci,2002; 43(8):2704-2713.
[106]蔡维,徐克勤,李国保.原发性开青患者房水内皮素的检测.临床眼科杂志,2000；8(6)：424—425.
[107]魏敏,符本琪,王延俊,等.原发性开角型青光眼房水内皮素与眼压的相关关系研究.临床眼科杂志,2000;8(5)：344—345.
[108]岑志敏,张庆平.内皮素—1与青光眼视神经损害.广西医学,2005；27(7)：1040—1042.
[109]郑晓光,杨新光,王为农,等.血液中一氧化氮和内皮素与开青的关系.眼科研究,2001；19(3)：269-270.
[110]严灿荣,梁轩伟.青光眼视功能损害中内皮素—1的作用及其机制.中国临床康复,2005；9(14)：156—157.
[111]彭清华,朱文锋,李传课,等.原发性闭角型青光眼患者血浆内皮素改变与中医证型关系的研究.中国中医眼科杂志,2000；10(4)：207—210.
[112]傅东红,王安悦.急性闭角型青光眼血浆内皮素-1水平的变化.眼科新进展,2002；22(6)：408—409.
[113]李志辉.青光眼,北京：北京科学技术出版社,1999：28—33.
[114]周文炳.临床青光眼,北京：人民卫生出版社,2000,2：60—62.
[115]佘华宁,王蔼青.啤酒降低眼压的临床观察.陕西医学杂志,1995；11(24)：671—672.
[116]Shields MB.Textbook of glaucoma.3rded.Baltimore:Williams&Wilkins,1992:45-75.
[117]李汶霞,李清美,王志新,等.缺血性脑血管病患者血浆内皮素水平昼夜节律变化的研究.微循环学杂志,1998；8(2)：20—22.
[118]林允信,刘允泰,王育敏,等.肺心病急性期动、静脉血浆内皮素-1昼夜含量比较.中华内科杂志,1994；33(10)：696.
[119]Young MW, Jackson FR, Shin HS, et al.A biological clock in drosophila. Cold Spring Harbor Symp Quent Biol,1985; 50:865-875.
[120]Simonson MS, Dunn MJ. Endothelins, A family of regulatory pep-tides. Hyperten-sion,1991; 6:856-863.
[121]ElherikK, KhanF, McLarenM, etal.Circadian variation invascular tone and endoth-elial cell functioninnor malmales.Clin Sci,2002; 102:547-552.
[1]葛坚.眼科学,北京：人民卫生出版社,2002：142.
[2]Neville N. Osborne, Glyn Chidlow, et al. The potential of neuroprotection in glaucoma treatment. Cur-rent Opinion in Ophthalmology,1999,10:82.
[3]Caprioli J. Neuroprotection of the optic nerve in glaucoma. Acta Ophthalmol,1994, 75:364.
[4]Yoles E, Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthal-mol,1998,42:367.
[5]Nickells RW. Retinal ganglion cell death in glaucoma:the how, the why and the maybe.J Glaucoma,1996,5:345.
[6]Mckinnon SJ:Glaucoma, appoptosis and neuroprotection. Curr Opin Ophthalmol, 1997,8:28.
[7]Otori Y, Wei JY, Bamstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci,1998,39:972.
[8]Ge Jian, Wenbing Zhou.et al. The study of relationships among the damage of visual function and hemorrheology, ocular rheography, and other influencing factors in glaucomatous patients. Eye Science,1993,9(1):3.
[9]葛坚.青光眼与神经细胞诱向因子.眼科学报,1997；13(2)：100.
[10]吴永青,葛坚.视网膜神经节细胞培养、纯化及生物学特性研究.中华眼科杂志,1999；35(3)：190.
[11]葛坚,吴永青.N-甲基天门冬氨酸和地塞米松对体外培养鼠视网膜神经节细胞凋亡作用观察.眼科学报,1999；15(2)：65.
[12]Oku H, et al. Surv Ophthalmol,1999,44(Suppl):S74.
[13]Neufeld AH,et al.Proc Natl Acad Sci USA,1999,96:9944.
[14]Dreyer EB,et al.J Glaucoma,1998,7:62.
[15]Osborne N, et al. Surv Ophthalmol,1999,43(Suppl):102.
[16]Levin LA,Schlamp CL,Spieldoch RL.et al. Identification of the bcl-2 family of genes in the rat retina.Invest Ophthalmol Vis Sci.1997,38:2545.
[17]Biose LH, Thompson CB. Bcl-xl can inhibit apoptosisin cells that have undergone Fas-induced protease activation.Proc Natl Acad Sci USA.1997,94:3759.
[18]谷雄霜,方爱武,谢丛森.中西医结合治疗晚期青光眼临床分析.中国中医眼科杂志,1996；6(4)：225.
[19]秦大军,祝素英.中药在青光眼术后的作用观察.中国中医眼科杂志,1997；7(3):184.
[20]毕留彬,毕泗松.杞菊地黄汤对原发性开角型青光眼术后增视效果的观察.中西医结合眼科杂志,1996；14(4)：240.
[21]张晓辉.通窍明目汤对原发性闭角型青光眼术后视神经保护作用的临床研究[C].2005.5：1—37.
[22]王万杰,周华祥,缪馨.王明芳教授治疗青光眼围手术期的经验.成都中医药大学学报,2007；30(4)：18.
[23]刘芳琼,龚华,刘照耀,等.石斛夜光丸加减治疗晚期青光眼术后28例总结.湖南中医杂志,2005；21(4)：22.
[24]代明山,阿拉坦图雅.蒙药治疗术后晚期青光眼.中医药学刊,2005；23(10)：1918.
[25]王静波,陈美荣,李伯勤,等.益阴明目合剂对高眼压大鼠超微结构的影响.吉林中医药,2008；28(1)：59-61.
[26]宿艳.益气养阴开窍法在中晚期青光眼视神经保护中的应用[C].2006,4：1—27.
[27]周峻,钱爱华.川芎嗪穴位注射对青光眼术后视功能保护的临床观察.湖北中医杂志,2007;29(7)：33—34.
[28]夏勇.关于针刺改善青光眼视功能损害机理的研究进展.河南中医学院学报,,2006；21(2)：87-88.
[29]周金黄.中药药理学,上海：上海科学出版社,1985：190—192.
[30]陈可冀,张之南,梁子钧,等.中西医结合研究丛书,上海：上海科学技术出版社,1990：509—523.
[31]李公宝,郭宝强.四甲基吡嗪抗血小板活性及抗栓治疗.中国微循环杂志,1997；5：110—112.
[32]施月欢,邹秀兰.川芎嗪对大鼠缺血再灌注视网膜SOD.MDA和NO水平及细胞凋亡的影响.中国实用眼科杂志,2002；20(1)：25.
[33]宋宗明,崔守信,张得秀.川芎嗪对兔眼高压下的视网膜神经节细胞和双极细胞损伤的保护作用.第四军医大学学报,2001；22(6)：514—516.
[34]刘杏,周文炳,葛坚,等.中药川芎嗪治疗原发性开角性青光眼视功能损害的疗效.中国实用眼科杂志,1999；17(1)：14.
[35]贺玉红,周樱.川芎嗪联合弥可保对晚期青光眼术后增视疗效观察.中国医药导报,2008；5(24)：207.
[36]李兴英,李公宝,杨连洲.原发性开角型青光眼微循环改变及临床意义.中国微循环杂志,1998；2：168—170.
[37]李兴英,杨连洲,康凤英,等.川芎嗪对兔高眼压视神经轴突损伤保护作用的研究.中华眼科杂志,2000；36(6)：442—444.
[38]葛坚.青光眼视功能损害与血液流变学、眼血流图及其它诸影响因素相互关系的研究.中华眼科杂志,1992；28(4)：195.
[39]吕世荣,王桂荣,佟琪,等.原发性开角型青光眼的血液流变学测定.眼科研究,1992；10：(4)：257—259.
[40]李钟秀,史蕙苓,陈程,等.原发性青光眼血浆血管紧张素Ⅱ测定的初步报告.眼科研究,1993；11(1)：38—39.
[41]李国彦.青光眼的现代诊疗,武汉：湖北科学技术出版社,1990,1：34—85.
[42]彭清华,朱惠安,李伟力.增视Ⅰ号治疗抗青光眼手术后患者114例的临床观察.中国医药学报.1994：9(3)：25—26.
[43]彭清华,罗萍,李传课,等.青光安颗粒对青光眼术后患者作用的临床研究.中国中医眼科杂志,1997；7(3)：151—155.
[44]彭清华,李建超.青光安治疗抗青光眼术后患者临床研究.湖南中医学院学报.2004；24(2)：36—39.
[45]郭跃侠,吴惠群,雷嘉启.葛根素治疗青光眼的研究现状与展望.中国中医眼科杂志,2002；12(2)：182—184.
[46]吴正红,刘有潜,朱延勤,等.葛根素滴眼液对家兔眼内压的作用.中国药科大学学报,1998；29(5)：387—389.
[47]王昌鹏,杨新光,王晓娟.几种中药对青光眼视网膜节细胞的保护作用.中国实用眼科杂志,2004；22(3)：164—166.
[48]张敏,张秋玲,叶润才.中西医结合改善晚期青光眼术后视功能的疗效观察.新中医,2005；37(6)：58—59.
[49]杜宁静,陈琦.复方丹参滴丸对闭角型青光眼患者红细胞免疫功能的影响.眼科研究,2003；21(3)：312.
[50]秦大军,张义平.复方丹参液对晚期青光眼术后增视作用的临床研究.中西医结合眼科杂志,1998；16(2):74.
[51]张人伟.灯盏花黄酮类成分的分离鉴定.中草药,1988；19：7.
[52]蒋幼芹,吴振中,莫杏君.眼压已控制的晚期青光眼治疗的探讨.眼科研究,1991；9(4)：229—232.
[53]罗旭异,高健生.中医眼科围手术期治疗的现状与展望.中国中医眼科杂志,2001； 11 (2)：118.
[54]陈明英,中医药在青光眼手术前后的应用体会.河南中医,200；26(9)：31
[55]方国新.顽固性青光眼术前毫针前房穿刺降压效果.中医医结合眼科杂志,1996；14(4)：241.
[56]胡玉春.针灸治疗急性闭角型青光眼.中医医结合眼科杂志,1995；13(4):258.
[57]秦大军,祝素英.中药在青光眼术后的作用观察.中国中医眼科杂志,1997；7(3)：184.
[58]付晓民.白内障及青光眼术后应用三七胶囊疗效观察.中国中医眼科杂志,1997；7(2)：115.
[59]韩红波,柏超然.青光眼滤过术后前房积血的中西医结合治疗和原因分析.中国中医眼科杂志,2001；11(3)：162—163.
[60]姜道平,魏鸿友,董玉根.中西医结合治疗青光眼术后反应.中西医结合眼科杂志,1997；15(2)：85—86.
[61]韩其江,李智敏.活血化瘀法治疗急性充血性青光眼术后反应.中西医结合眼科杂志,1994；12(3)：181.
[62]陈明英,中医药在青光眼手术前后的应用体会.河南中医,2006；26(9)：31.
[63]石守礼.泻肝解郁汤加减治疗青光眼.新中医,1986；10：31.
[64]汤爱灿.中医西结合治疗滤过性抗青光眼术后前房迟缓形成的疗效观察.海南医学,2001；12(4)：44.
[65]许晓平,崔艳红,沈玲,等.泻肝利水法治疗滤过性手术后前房延缓形成临床观察.中国中医眼科杂志,1997；7(1)：45.
[66]郑恕远,杜志山,杨万期.八珍汤合五苓散加减治疗滤过性抗青光眼术后前房迟延形成临床观察.中国中医眼科杂志,1995；5(1)：32.
[67]王建君,龚时贤.青光眼滤过术后浅前房的中西医结合治疗.浙江临床医学,2002；4(3)：197.
[68]陈瑛,陈金华.中西医结合治疗青光眼滤过术后浅前房.浙江中西医结合杂志,2000；10(3)：171.
[69]杨树立,张坤丽,张凤英,等.中西医结合治疗青光眼晚期浅／无前房.中西医结合眼科杂志,1995；13(3)：133—134.
[70]杨海燕.补阳还五汤治疗滤过性手术后前房延缓形成临床观察.中国中医眼科杂 志,1999；9(1)：39.
[71]陈静琪,余晓临,杨国华.综合治疗青光眼术后前房延缓形成.中国中医眼科杂志,1994：4(1)：18.
[72]张玲,马小丽.青光眼术后低眼压综合征的中医治疗.北京中医,2006；25(3)：161—162.
[73]葛坚,孙兴怀,王宁利.现代青光眼研究进展,南京：江苏科学技术出版社,2000：68—70.